Cockayne Syndrome

Cockayne Syndrome

Introduction

Cockayne Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cockayne syndrome (CS) is a rare, autosomal recessive multisystem disorder caused by mutations in the ERCC8 (CSA) or ERCC6 (CSB) genes, which encode proteins essential for transcription-coupled nucleotide excision repair (TC-NER). The resulting impairment in DNA damage repair leads to progressive neurodegeneration, cachectic dwarfism, photosensitivity, and premature aging features. First described by Edward Alfred Cockayne in 1936, the syndrome is one of a small group of nucleotide excision repair (NER) disorders that includes xeroderma pigmentosum and trichothiodystrophy ([Cockayne, 1936](https://doi.org/10.1136/adc.11.61.1); [Laugel, 2013](https://pubmed.ncbi.nlm.nih.gov/23852455/)). [@overexpression]

Cockayne syndrome is characterized by postnatal growth failure, progressive microcephaly, and progressive neurological deterioration including cerebellar atrophy. The neurodegeneration in CS distinguishes it from other NER-deficient conditions and is thought to result from a combination of defective DNA repair, transcriptional dysregulation, [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction), and impaired [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy) ([Karikkineth et al., 2017](https://doi.org/10.1016/j.mad.2016.12.005)). [@swallowing]

Epidemiology

Cockayne Syndrome

Introduction

Cockayne Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cockayne syndrome (CS) is a rare, autosomal recessive multisystem disorder caused by mutations in the ERCC8 (CSA) or ERCC6 (CSB) genes, which encode proteins essential for transcription-coupled nucleotide excision repair (TC-NER). The resulting impairment in DNA damage repair leads to progressive neurodegeneration, cachectic dwarfism, photosensitivity, and premature aging features. First described by Edward Alfred Cockayne in 1936, the syndrome is one of a small group of nucleotide excision repair (NER) disorders that includes xeroderma pigmentosum and trichothiodystrophy ([Cockayne, 1936](https://doi.org/10.1136/adc.11.61.1); [Laugel, 2013](https://pubmed.ncbi.nlm.nih.gov/23852455/)). [@overexpression]

Cockayne syndrome is characterized by postnatal growth failure, progressive microcephaly, and progressive neurological deterioration including cerebellar atrophy. The neurodegeneration in CS distinguishes it from other NER-deficient conditions and is thought to result from a combination of defective DNA repair, transcriptional dysregulation, [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction), and impaired [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy) ([Karikkineth et al., 2017](https://doi.org/10.1016/j.mad.2016.12.005)). [@swallowing]

Epidemiology

Cockayne syndrome is a rare disorder with an estimated prevalence of approximately 2-3 per million in Western Europe: [@ercc]

• Incidence: Approximately 1 in 200,000 births in Western Europe ([Kleijer et al., 2008](https://doi.org/10.1016/j.dnarep.2008.01.007))
• Higher prevalence regions: Founder effects have been noted in some isolated populations
• Sex distribution: Affects males and females equally (autosomal recessive)
• Complementation groups: ~80% of patients belong to the CS-B group (ERCC6 mutations); ~20% to the CS-A group (ERCC8 mutations)
• Carrier frequency: Estimated at approximately 1 in 250 in the general population

Classification and Clinical Subtypes

Cockayne syndrome is classified into three clinical subtypes based on severity and age of onset: [@csa]

Type I (Classic/Moderate Form)

• Onset: Normal prenatal growth; symptoms appear in the first 1-2 years of life
• Key features: Progressive growth failure, microcephaly, intellectual disability, cerebellar ataxia, spasticity, sensorineural hearing loss, and pigmentary retinopathy
• Course: Gradual neurological decline with loss of motor and cognitive milestones
• Life expectancy: Typically 10-20 years, with death from respiratory infection or organ failure
• Genetics: Most commonly associated with ERCC8 (CSA) mutations

Type II (Severe/Connatal Form)

• Onset: Symptoms present at birth or within the first weeks of life
• Key features: Severe prenatal growth restriction, congenital cataracts, arthrogryposis, minimal neurological development, and early-onset kyphosis
• Course: Rapid neurological deterioration with minimal developmental milestones achieved
• Life expectancy: Usually less than 5-7 years
• Genetics: More commonly associated with severe ERCC6 (CSB) mutations

Type III (Mild/Late-Onset Form)

• Onset: Later childhood to adolescence
• Key features: Milder growth failure, preserved intellectual function for longer periods, photosensitivity, and slowly progressive neurological symptoms
• Course: Slower progression than Types I and II
• Life expectancy: Can survive into the third decade or beyond
• Genetics: Associated with hypomorphic mutations in either CSA or CSB

Genetics and Molecular Biology

The ERCC8 (CSA) Gene

The ERCC8 gene is located on chromosome 5q12.1 and encodes the Cockayne Syndrome A (CSA) protein, a 44 kDa WD-repeat protein that functions as a component of a DDB1-CUL4-based E3 ubiquitin ligase complex ([Fischer et al., 2011](https://doi.org/10.1016/j.cell.2011.10.014)): [@rna]

• Structure: Contains 7 WD40 repeats that form a beta-propeller domain
• Function: Acts as a substrate receptor for the CRL4-CSA E3 ubiquitin ligase, targeting specific proteins for ubiquitination during TC-NER
• Key substrates: Ubiquitinates RNA polymerase II (RNAPII) stalled at DNA lesions, facilitating its degradation and allowing access for repair factors
• Pathogenic variants: Over 30 disease-causing mutations identified, including missense, nonsense, splice-site, and frameshift variants

The ERCC6 (CSB) Gene

The ERCC6 gene is located on chromosome 10q11.23 and encodes the Cockayne Syndrome B (CSB) protein, a 168 kDa member of the SWI/SNF family of ATP-dependent chromatin remodelers: [@cellular]

• Structure: Contains 7 conserved ATPase motifs characteristic of SWI2/SNF2 DNA-stimulated ATPases
• Function: CSB protein is a multifunctional protein involved in TC-NER, general transcription, chromatin remodeling, and mitochondrial maintenance
• Role in TC-NER: Recruited to sites of stalled RNAPII, where it uses ATP hydrolysis to remodel chromatin and facilitate repair factor access
• Pathogenic variants: Over 80 disease-causing mutations identified

Transcription-Coupled Nucleotide Excision Repair (TC-NER)

The primary repair pathway disrupted in Cockayne syndrome involves the following steps: [^11]

In CS, defective TC-NER leads to persistent transcription blockage at DNA lesions, triggering apoptotic cell death pathways, particularly in [neurons](/entities/neurons) and other postmitotic cells ([Hanawalt & Spivak, 2008](https://doi.org/10.1038/nrm2457)). [^12]

Neuropathology

The neuropathology of Cockayne syndrome is distinctive and includes features of both impaired development and neurodegeneration: [^13]

Macroscopic Features

• Microcephaly: Progressive brain volume loss, often beginning in the first year
• Brain weight: Typically reduced to 50-75% of age-matched normal
• Cerebral atrophy: Prominent cortical thinning and ventricular enlargement
• Cerebellar atrophy: Marked loss of Purkinje cells and granule cells
• Calcifications: Patchy mineralization in the [basal-ganglia](/brain-regions/basal-ganglia), [cortex](/brain-regions/cortex), and [cerebellum](/brain-regions/cerebellum)

Microscopic Features

• Tigroid demyelination: Patchy loss of myelin with preserved perivascular myelin, creating a characteristic "tigroid" or leopard-skin pattern
• [oligodendrocytes](/entities/oligodendrocytes) loss: Reduction in oligodendrocyte density, particularly in severely affected white matter regions
• Neuronal loss: Widespread but especially prominent in the [cerebellum](/brain-regions/cerebellum) (Purkinje and granule cells) and [cortex](/brain-regions/cortex)
• Axonal spheroids: Swollen axons indicating disrupted [axonal-transport-defects](/mechanisms/axonal-transport-defects)
• Vascular changes: Thickened vessel walls with calcium deposits (calcifying microangiopathy)
• Gliosis: Reactive [astrocytes](/cell-types/astrocytes) proliferation throughout affected regions

Retinal and Cochlear Degeneration

• Progressive loss of photoreceptors with pigmentary retinopathy (salt-and-pepper pattern)
• Cochlear degeneration with loss of hair cells and spiral ganglion [neurons](/entities/neurons)
• Vestibular dysfunction contributing to balance impairment

Pathogenesis: Beyond DNA Repair

While defective TC-NER is the hallmark molecular defect, research has revealed additional pathogenic mechanisms that contribute to the neurodegeneration and premature aging in CS: [^15]

Mitochondrial Dysfunction

CSB protein has been found to localize to [mitochondrial-dynamics](/entities/mitochondrial-dynamics) and play roles in mitochondrial DNA (mtDNA) maintenance: [^16]

• CS cells show increased [oxidative-stress](/mechanisms/oxidative-stress) production
• Impaired mitochondrial membrane potential and respiratory chain function
• Defective mitophagy leading to accumulation of damaged mitochondria
• Reduced NAD+ levels due to hyperactivation of PARP1 by unrepaired DNA damage

NAD+ Depletion

A critical discovery linking DNA repair defects to neurodegeneration is the NAD+ depletion pathway: [^18]

This pathway represents a potential therapeutic target, as NAD+ supplementation has shown benefit in CS mouse models ([Scheibye-Knudsen et al., 2014](https://doi.org/10.1016/j.celrep.2014.01.034); [Fang et al., 2016](https://doi.org/10.1073/pnas.1515855113)). [^19]

Transcriptional Dysregulation

Beyond their roles in DNA repair, CSA and CSB proteins participate in transcriptional regulation: [^20]

• CSB regulates ribosomal RNA transcription and ribosome biogenesis
• Loss of CSB leads to altered gene expression profiles, particularly in neuronal differentiation pathways
• Disrupted epigenetic regulation including aberrant [dna-methylation](/entities/dna-methylation) and [histone-modifications](/entities/histone-modifications)

Impaired Autophagy

• CS cells show defective [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy) and impaired clearance of damaged organelles
• Reduced [tfeb](/proteins/tfeb) nuclear translocation and lysosomal biogenesis
• Accumulation of lipofuscin and other cellular debris, contributing to premature aging phenotype

Clinical Features

Neurological Manifestations

• Cognitive: Progressive intellectual disability; some patients develop normally initially before declining
• Motor: Progressive spasticity, cerebellar ataxia, tremor, and contractures
• Peripheral neuropathy: Demyelinating sensorimotor neuropathy
• Seizures: Occur in a minority of patients, more common in severe forms
• Microcephaly: Progressive, often the earliest detectable sign

Ophthalmological Features

Ocular involvement is a hallmark of Cockayne syndrome, with progressive retinal and anterior segment changes:

• Pigmentary retinopathy: A progressive "salt-and-pepper" pattern of retinal pigmentation affecting approximately 60% of patients. Fine pigmentary changes begin peripherally and progress centrally, eventually leading to macular atrophy. Ultra-wide-field retinography and autofluorescence imaging reveal diffuse pigment redistribution ([Dollfus et al., 2003](https://pubmed.ncbi.nlm.nih.gov/1443019/))
• Electroretinographic abnormalities: Full-field ERG demonstrates progressive cone and rod dysfunction, with marked reduction in both photopic and scotopic responses. Visual function may be preserved despite significant electrophysiological abnormalities in earlier stages ([Traboulsi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30820731/))
• Cataracts: Occur in 15–36% of patients; lens opacities may be nuclear or posterior subcapsular. In Type II (connatal) CS, cataracts can be congenital
• Optic atrophy: Disc pallor is frequently associated with retinal degeneration but may precede retinal changes; contributes to progressive visual loss
• Enophthalmos: Sunken eyes due to loss of periorbital fat, contributing to the characteristic facial appearance
• Other findings: Miotic pupils, decreased or absent tear production, strabismus, nystagmus, photophobia, and narrowed retinal arterioles ([Karikkineth et al., 2017](https://doi.org/10.1016/j.mad.2016.12.005); [Nance & Berry, 1992](https://pubmed.ncbi.nlm.nih.gov/30252254/))

Auditory Features

Auditory impairment is a cardinal feature of Cockayne syndrome, present in over 50% of patients:

• Sensorineural hearing loss: Progressive, beginning with high-frequency loss and advancing to involve speech frequencies. Onset typically occurs in the second year of life for Type I CS. Severity ranges from mild to profound, and progression parallels neurological decline
• Cochlear pathology: Loss of inner and outer hair cells and degeneration of spiral ganglion [neurons](/entities/neurons), with preferential loss in the basal (high-frequency) cochlear turn
• Central auditory pathway involvement: Cell loss occurs at multiple sites along the auditory pathway, from the cochlea to the auditory [cortex](/brain-regions/cortex), contributing to auditory processing deficits beyond peripheral hearing loss
• NAD+ depletion link: Short-term NAD+ supplementation with nicotinamide riboside prevented hearing loss in CS mouse models (Csb^m/m), linking the NAD+ depletion pathway to auditory pathology ([Okur et al., 2020](https://www.nature.com/articles/s41514-019-0040-z))
• Vestibular dysfunction: Progressive vestibular impairment contributing to balance difficulties and worsening the gait ataxia from cerebellar involvement
• Hearing aids: Amplification devices are recommended early to support language and cognitive development ([Wilson et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26969326/))

Growth and Skeletal Features

Growth failure is a defining feature of Cockayne syndrome, driven by both metabolic impairment and hormonal dysregulation:

• Postnatal growth failure: Normal birth weight and length, with progressive growth deceleration beginning in the first 1–2 years. Height, weight, and head circumference fall well below the 5th percentile by age 3–5 in Type I CS
• Cachectic dwarfism: Extreme thinness with loss of subcutaneous fat and muscle wasting, resulting in a prematurely aged appearance. Adult height is typically 100–130 cm in Type I CS
• Disproportionate body habitus: Relatively long limbs with large hands and feet compared to the trunk; a long, narrow face and prominent ears
• Bird-like facies: Characteristic craniofacial features include a narrow face, prominent nose and ears, sunken eyes (enophthalmos), micrognathia, and thin skin
• Progressive microcephaly: Brain growth failure leading to an increasingly small head circumference relative to body size
• Kyphosis and joint contractures: Progressive thoracolumbar kyphosis with flexion contractures at hips, knees, and elbows, limiting mobility
• Skeletal changes: Thickened calvarium, sclerotic phalanges, and osteoporosis; vertebral body changes may contribute to spinal deformity
• Dental abnormalities: Severe dental caries, small and malformed teeth, enamel hypoplasia, and early tooth loss ([Karikkineth et al., 2017](https://doi.org/10.1016/j.mad.2016.12.005); [Natale, 2011](https://pubmed.ncbi.nlm.nih.gov/21235446/))

Cutaneous Features

Cutaneous manifestations reflect both the DNA repair deficiency and the accelerated aging process:

• Photosensitivity: Present in approximately 75% of patients; manifests as facial erythema in a butterfly distribution following sun exposure, due to defective transcription-coupled nucleotide excision repair (TC-NER). While acute sensitivity may diminish over time, chronic changes including telangiectasia, mottled pigmentation, scarring, and cutaneous atrophy persist at photoexposed sites
• Thin, dry skin: Progressive loss of subcutaneous fat and dermal thinning, contributing to the prematurely aged appearance. Skin becomes taut and parchment-like
• Cool, cyanotic extremities: Peripheral vasomotor instability leading to cold hands and feet with cyanotic discoloration; may also present with Raynaud-like symptoms
• Anhidrosis: Decreased or absent sweating, recently identified as a feature particularly in ERCC8 (CSA) patients, contributing to heat intolerance ([Zhang et al., 2025](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1591551/full))
• Hair changes: Thin, sparse hair; may show premature graying
• Lipodystrophy: Loss of subcutaneous adipose tissue, particularly in the face and extremities ([Laugel, 2013](https://pubmed.ncbi.nlm.nih.gov/23852455/))

Other Features

• Dental caries and enamel hypoplasia
• Hepatomegaly and elevated liver enzymes
• Hypertension
• Anhidrosis (decreased sweating; recently identified as a feature in ERCC8 patients)

Diagnosis

Clinical Criteria

Diagnosis of Cockayne syndrome is based on the combination of:

Neuroimaging

• MRI: White matter hypomyelination/demyelination, cerebral and cerebellar atrophy, [basal-ganglia](/brain-regions/basal-ganglia) calcifications
• CT: Calcifications in the basal ganglia, cerebral [cortex](/brain-regions/cortex), and cerebellum are highly characteristic
• MR Spectroscopy: May show reduced NAA (N-acetylaspartate) and increased choline/creatine ratio

Laboratory Testing

• UV sensitivity assay: Cultured fibroblasts show impaired recovery of RNA synthesis (RRS) after UV irradiation — the gold standard functional test
• Genetic testing: Sequencing of ERCC6 and ERCC8 genes; gene panels for NER disorders
• Prenatal diagnosis: Available via molecular testing when familial mutations are known

Treatment and Management

Current Standard of Care

There is currently no cure for Cockayne syndrome, and management is symptomatic and supportive:

• Feeding support: Gastrostomy tube feeding for patients with swallowing difficulties
• Physical therapy: To manage spasticity and contractures
• Sun protection: Strict UV avoidance and sunscreen for photosensitive patients
• Hearing aids: For sensorineural hearing loss
• Ophthalmological care: Cataract removal, monitoring for retinal degeneration
• Dental care: Regular monitoring and treatment of dental caries
• Seizure management: Antiepileptic medications when needed

Emerging Therapeutic Approaches

NAD+ Supplementation

Based on the discovery that NAD+ depletion drives pathology in CS:

• Nicotinamide riboside (NR): NAD+ precursor that has shown efficacy in CS mouse models, rescuing neuronal phenotypes and extending lifespan ([Fang et al., 2016](https://doi.org/10.1073/pnas.1515855113))
• PARP inhibitors: By reducing PARP1-mediated NAD+ consumption, these may preserve cellular NAD+ pools

Gene Therapy

• AAV-based gene therapy: A 2025 study described development of an AAV vector encoding human CSA under a CBA promoter for Cockayne syndrome type A, demonstrating proof-of-concept in preclinical models ([Martin et al., 2025](https://www.biorxiv.org/content/10.1101/2025.06.06.658349v1))
• Gene replacement approaches for both CSA and CSB are under development

Mitophagy Induction

Enhancing clearance of damaged [mitochondrial-dynamics](/entities/mitochondrial-dynamics) through [mitophagy](/mechanisms/mitophagy) represents a therapeutic strategy in CS:

• [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration) inhibition: Rapamycin and its analogs (rapalogs) inhibit mTORC1, promoting [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy) and [mitophagy](/mechanisms/mitophagy) to clear dysfunctional mitochondria. Rapamycin treatment has shown benefit in CS cellular models by restoring mitochondrial membrane potential and reducing [oxidative-stress](/mechanisms/oxidative-stress) accumulation
• SIRT1 activation: Because SIRT1 activity is reduced in CS cells due to NAD+ depletion, sirtuin-activating compounds (e.g., resveratrol, SRT1720) may enhance mitochondrial biogenesis through the SIRT1-PGC-1alpha axis
• Urolithin A: A natural mitophagy inducer that promotes PINK1-Parkin-dependent mitophagy; under investigation for age-related mitochondrial dysfunction
• Combined approaches: The NAD+/mitophagy axis may be most effectively targeted through combined NAD+ supplementation and mitophagy enhancement, addressing both the metabolic deficit and organelle quality control failure ([Scheibye-Knudsen et al., 2014](https://doi.org/10.1016/j.celrep.2014.01.034))

Relationship to Other Neurodegenerative Diseases

Cockayne syndrome shares mechanistic features with several other neurodegenerative conditions, providing insights into common pathogenic pathways ([Scheibye-Knudsen et al., 2014](https://doi.org/10.1016/j.celrep.2014.01.034); [Karikkineth et al., 2017](https://doi.org/10.1016/j.mad.2016.12.005)):

• DNA damage/repair disorders: CS belongs to the family of NER disorders alongside xeroderma pigmentosum (XP), trichothiodystrophy (TTD), and UV-sensitive syndrome. XP/CS overlap patients with mutations in XPB, XPD, or XPG show combined features of both disorders
• Premature aging syndromes: Like Werner syndrome, Bloom syndrome, and Hutchinson-Gilford progeria, CS features accelerated aging phenotypes. These progeroid syndromes share disrupted DNA damage response pathways and NAD+ depletion ([Fang et al., 2016](https://doi.org/10.1073/pnas.1515855113))
• [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction): The role of mitochondrial impairment in CS pathogenesis parallels findings in [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), and other age-related neurodegenerative diseases, suggesting convergent mitochondrial mechanisms
• NAD+ metabolism: NAD+ depletion as a disease mechanism connects CS to ongoing research in age-related neurodegeneration and metabolic decline. NAD+ supplementation strategies developed for CS (nicotinamide riboside, nicotinamide mononucleotide) are being explored in [alzheimers](/diseases/alzheimers-disease) clinical trials ([Hikosaka et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39611850/))
• Cerebellar neurodegeneration: CS shares features of cerebellar atrophy with [spinocerebellar-ataxia](/diseases/spinocerebellar-ataxia), [friedreichs-ataxia](/diseases/friedreichs-ataxia), and [ataxia-telangiectasia](/diseases/ataxia-telangiectasia), all involving selective vulnerability of [purkinje-cells](/cell-types/purkinje-cells) and granule [neurons](/entities/neurons)

External Links

• [OMIM: Cockayne Syndrome A (216400)(https://omim.org/entry/216400)
• [OMIM: Cockayne Syndrome B (133540)(https://omim.org/entry/133540)
• [GeneReviews: Cockayne Syndrome](https://www.ncbi.nlm.nih.gov/books/NBK1342/)
• [Orphanet: Cockayne Syndrome](https://www.orpha.net/en/disease/detail/191)

See Also

• [purkinje-cells](/cell-types/purkinje-cells)

Background

The study of Cockayne Syndrome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Mechanisms of transcription-coupled repair and DNA damage surveillance in health and disease.](https://pubmed.ncbi.nlm.nih.gov/41254380/) (2026 Mar) - Nature reviews. Molecular cell biology
• [Overexpression of Ku80 Protects Lens Epithelial Cells from Selenium-Induced Cataract Formation by Regulating the DNA Damage Response.](https://pubmed.ncbi.nlm.nih.gov/41114541/) (2026 Mar) - Current eye research
• [Swallowing and Communication in Cockayne Syndrome: Clinical Characteristics and Management.](https://pubmed.ncbi.nlm.nih.gov/41730799/) (2026 Feb 23) - American journal of medical genetics. Part A
• [ercc6 deficient zebrafish exhibit UV and metronidazole sensitivity, increased oxygen consumption, and impaired hair cell mechanoelectrical transduction which can be restored by the superoxide dismutase mimetic MnTBAP.](https://pubmed.ncbi.nlm.nih.gov/41527836/) (2026 Feb 23) - Human molecular genetics
• [Repurposing Alkylating Agents in Melanoma via ERCC8 Silencing: A Novel Therapeutic Strategy.](https://pubmed.ncbi.nlm.nih.gov/41749901/) (2026 Feb 17) - Cancers

Visual Summary

Key Pathway Steps:

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References